Cross-reactive memory T cells and herd immunity to SARS-CoV-2.


Journal

Nature reviews. Immunology
ISSN: 1474-1741
Titre abrégé: Nat Rev Immunol
Pays: England
ID NLM: 101124169

Informations de publication

Date de publication:
11 2020
Historique:
accepted: 25 09 2020
pubmed: 8 10 2020
medline: 4 11 2020
entrez: 7 10 2020
Statut: ppublish

Résumé

Immunity is a multifaceted phenomenon. For T cell-mediated memory responses to SARS-CoV-2, it is relevant to consider their impact both on COVID-19 disease severity and on viral spread in a population. Here, we reflect on the immunological and epidemiological aspects and implications of pre-existing cross-reactive immune memory to SARS-CoV-2, which largely originates from previous exposure to circulating common cold coronaviruses. We propose four immunological scenarios for the impact of cross-reactive CD4

Identifiants

pubmed: 33024281
doi: 10.1038/s41577-020-00460-4
pii: 10.1038/s41577-020-00460-4
pmc: PMC7537578
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

709-713

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI142742
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N9301900065
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI42742
Pays : United States

Références

Bull Math Biol. 2012 Sep;74(9):2125-41
pubmed: 22829179
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
J Immunol. 2011 Dec 1;187(11):5510-4
pubmed: 22058417
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
JAMA. 2020 Oct 6;324(13):1279-1281
pubmed: 32915201
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Nat Immunol. 2014 Dec;15(12):1104-15
pubmed: 25396352
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Science. 2003 Jun 20;300(5627):1966-70
pubmed: 12766207
Science. 2020 Aug 14;369(6505):846-849
pubmed: 32576668
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20365-70
pubmed: 19918065
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Science. 2014 Oct 3;346(6205):93-8
pubmed: 25170048
Immunity. 2016 Jun 21;44(6):1379-91
pubmed: 27287409
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
J Virol. 2020 May 4;94(10):
pubmed: 32132233
J Theor Biol. 2022 May 7;540:111063
pubmed: 35189135
Annu Rev Immunol. 2019 Apr 26;37:521-546
pubmed: 30726153
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
BMJ. 2020 Sep 17;370:m3563
pubmed: 32943427
Trends Microbiol. 1997 Jan;5(1):31-7
pubmed: 9025233
Immunity. 2020 Sep 15;53(3):487-495
pubmed: 32853545
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):787-92
pubmed: 24277828
bioRxiv. 2020 Jul 10;:
pubmed: 32676602
J Med Virol. 1984;13(2):179-92
pubmed: 6319590

Auteurs

Marc Lipsitch (M)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. mlipsitc@hsph.harvard.edu.

Yonatan H Grad (YH)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ygrad@hsph.harvard.edu.

Alessandro Sette (A)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. alex@lji.org.
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA. alex@lji.org.

Shane Crotty (S)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. shane@lji.org.
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA. shane@lji.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH